Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillermo Di Girolamo

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Current Drug Safety|March 12, 2010
Drug-induced at interval prolongation: clinical, safety and regulatory updaesGuillermo Di Girolamo
Expert Opinion on Drug Safety|October 10, 2012
Statins: safety and pharmacological interactionsGuillermo Di Girolamo, Claudio González
Expert Opinion on Drug Safety|March 1, 2006
Safety and side effects of the insulin analoguesClaudio D González, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Prokinetic agents and QT prolongation: a familiar scene with new actorsGuillermo Alberto Keller, Guillermo Di Girolamo
Expert Opinion on Pharmacotherapy|April 27, 2021
How do you treat obesity in the elderly pharmacologically?Claudio Daniel González, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Antihistamines: past answers and present questionsGuillermo Alberto Keller, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Antimicrobial agents-associated with QT interval prolongationFernando Bril, Claudio Daniel Gonzalez, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Other drugs acting on nervous system associated with QT-interval prolongationGuillermo Alberto Keller, Marcelo L Ponte, Guillermo Di Girolamo
Current Drug Safety|December 2, 2011
Pharmacovigilance and the cardiovascular system: two sides to every storyGuillermo Alberto Keller, Guillermo Di Girolamo, Paulino Antonio Alvarez
Expert Opinion on Pharmacotherapy|September 11, 2010
Nonresponders to clopidogrel: pharmacokinetics and interactions involvedMariano A Giorgi, Guillermo Di Girolamo, Claudio D González
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Current Drug Safety|March 12, 2010
Drug-induced at interval prolongation: clinical, safety and regulatory updaesGuillermo Di Girolamo
Expert Opinion on Drug Safety|October 10, 2012
Statins: safety and pharmacological interactionsGuillermo Di Girolamo, Claudio González
Expert Opinion on Drug Safety|March 1, 2006
Safety and side effects of the insulin analoguesClaudio D González, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Prokinetic agents and QT prolongation: a familiar scene with new actorsGuillermo Alberto Keller, Guillermo Di Girolamo
Expert Opinion on Pharmacotherapy|April 27, 2021
How do you treat obesity in the elderly pharmacologically?Claudio Daniel González, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Antihistamines: past answers and present questionsGuillermo Alberto Keller, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Antimicrobial agents-associated with QT interval prolongationFernando Bril, Claudio Daniel Gonzalez, Guillermo Di Girolamo
Current Drug Safety|March 10, 2010
Other drugs acting on nervous system associated with QT-interval prolongationGuillermo Alberto Keller, Marcelo L Ponte, Guillermo Di Girolamo
Current Drug Safety|December 2, 2011
Pharmacovigilance and the cardiovascular system: two sides to every storyGuillermo Alberto Keller, Guillermo Di Girolamo, Paulino Antonio Alvarez
Expert Opinion on Pharmacotherapy|September 11, 2010
Nonresponders to clopidogrel: pharmacokinetics and interactions involvedMariano A Giorgi, Guillermo Di Girolamo, Claudio D González
Pageof 7